Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd., to Develop and Commercialize YH002 (OX40 Antibody) and Two Undisclosed Active Ingredients as Components of the Syncrovaxâ„¢ Immunotherapy Platform
businesswire.com
news
2022-10-18 00:00:00

October 18, 2022 08:40 AM Eastern Daylight Time FORT LAUDERDALE, Fla. & BEIJING--(BUSINESS WIRE)--Syncromune, Inc., a clinical stage biopharmaceutical company focused on the development of combination intratumoral immunotherapy announced today that the Company has signed an exclusive worldwide license agreement for YH002 (OX40 antibody) and two other active ingredients with Eucure (Beijing) Biopharma Co., Ltd. ('Eucure'), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
